Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration.

ABSTRACT:

Background

The anti-PD-L1 antibody durvalumab has been approved for use in first-line advanced biliary duct cancer (ABC). So far, predictive biomarkers of efficacy are lacking.

Methods

ABC patients who underwent gemcitabine-based chemotherapy with or without durvalumab were retrospectively enrolled, and their baseline clinical pathological indices were retrieved from medical records. Overall (OS) and progression free survival (PFS) were calculated and analyzed. The levels of peripheral biomarkers from 48 patients were detected with assay kits including enzyme-linked immunosorbent assay. Genomic alterations in 27 patients whose tumor tissues were available were depicted via targeted next-generation sequencing.

Results

A total of 186 ABC patients met the inclusion crite

SUBMITTER: Lu Y 

PROVIDER: S-EPMC11377375 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature